HIV Prevention England Conference 2017 Update on the PrEP Impact Trial


Nalini Iyanger Public Health Specialty Trainee

18th May 2017

Centre for Infectious Disease Surveillance & Control



UK PrEP timeline



https://www.england.nhs.uk/2016/11/update-on-prep/ https://www.england.nhs.uk/2016/12/hiv-prevention-pregramme/





Address key outstanding questions

- 1) Proportion eligible for PrEP?
- 2) How to identify, engage and maintain all people eligible for PrEP?
- 3) Proportion accepting offer of PrEP?
- 4) Proportions choosing daily or intermittent dosing?
- 5) Duration of PrEP use?
- 6) Impact on HIV incidence?
- 7) Impact on STI incidence?

Primary objective

To measure PrEP-eligibility, PrEP-uptake, duration of PrEP-eligibility and duration of PrEP-use among Genitourinary Medicine (GUM) clinic attendees

Inclusion criteria

Key principles of the inclusion criteria:

Include all persons at high risk of HIV:

- 1. Higher risk sexual behaviour
- 2. HIV positive partner
- 3. Partner of unknown status and at high risk of HIV

Inclusion Criteria

Cis- and transgender MSM and trans women

a) HIV negative test in previous yearb) Report condomless sex in the previous 3 monthsc) Affirm likelihood of CSI in the next 3 months

2 HIV negative partner of an HIV positive person

a) HIV positive partner not known to be virally suppressedb) CSI anticipated before treatment of HIV positive partner takes effect

3 HIV negative person

Clinically assessed and considered to be at similar risk of HIV acquisition as those with a serodiscordant partner who is not known to be virally suppressed

First visit


- Baseline tests (HIV test, STI tests, Kidney function)
- 3-month PrEP prescription (daily or EBD)
- Routine data collection

Follow up visits

(1 month after starting and every 3 months)

- HIV/STI tests according to routine practice
- Hepatitis C test according to routine practice
- Kidney function
- Combination prevention
- Safety check
- PrEP prescription (daily or EBD)
- Routine data collection

Proposed trial timeline







Address key outstanding questions



Based on proposed eligibility criteria



Mitigate against future geographical inequity of access



Support regular clinical risk assessments as part of risk reduction



Use GUMCAD as data collection spine

Centre for Infectious Disease Surveillance & Control



PrEP Impact Trial



and



Protecting and improving the nation's health

Chief-Investigator: Professor Brian Gazzard – Chelsea and Westminster NHS Foundation Trust

Co-Investigators: Dr Anne Sullivan, Professor Sheena McCormack, Professor Noel Gill, Dr Monica Desai, Dr John Saunders, Dr Valerie Delpech

SSAT Trial Management and Co-ordination: Ruth Bateson, Carl Fletcher, Vanessa Tierney, Michal Seriacki, Mihir Vaghela, Marita Marshall, Paul Walsh, Hannah Reaney

Statistical Support: Dr Andre Charlett, Martina Furegato

Health Economist: KohJun Ong

Scientific and Technical Support: Nalini Iyanger, Victoria Hall, Hamish Mohammed, Sarika Desai, Linda Lazarus, Nigel Field, Gwenda Hughes

Communications support: Anthony Nardone, Luis Guerra, Kate Folkard, Kirsty Foster, Clare Cook.

Centre for Infectious Disease Surveillance & Control



Contact:

Dr Monica Desai - Monica.Desai@phe.gov.uk

Dr John Saunders - John.Saunders@phe.gov.uk

Centre for Infectious Disease Surveillance & Control

